An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits D Buskila, H Cohen, L Neuman, RP Ebstein Fibromyalgia (FMS) is a common syndrome consisting of diffuse aching, pain, or stiffness in the muscles or joints, accompanied by multiple tender points on examination. FMS patients are characterized by an atypical personality profile, high on harm avoidance and low on novelty seeking. The current study showed a decreased frequency in FMS of a dopamine D4 receptor polymorphism, the 7 repeat, associated in some studies with novelty seeking.
SCIENTIFIC CORRESPONDENCES
An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits D Buskila, H Cohen, L Neuman, RP Ebstein Fibromyalgia (FMS) is a common syndrome consisting of diffuse aching, pain, or stiffness in the muscles or joints, accompanied by multiple tender points on examination. FMS patients are characterized by an atypical personality profile, high on harm avoidance and low on novelty seeking. The current study showed a decreased frequency in FMS of a dopamine D4 receptor polymorphism, the 7 repeat, associated in some studies with novelty seeking.
Post-mortem evidence from human brain tissue of disturbed glucose metabolism in mood and psychotic disorders WT Regenold, P Phatak, MA Kling, P Hauser Reports of abnormal glucose metabolism in patients with mood and psychotic disorders predate modern psychopharmacology, suggesting a role in these disorders independent of medication effects. Using post-mortem brain tissue, the authors investigated the polyol (or 'sorbitol') pathway of glucose metabolism, because it is involved in nervous tissue disease in diabetes mellitus. They reported elevated sorbitol concentration in brains from nondiabetic individuals with schizophrenia, bipolar disorder and unipolar depression, compared to normal controls, suggesting a disturbance of brain glucose metabolism in these three disorders.
FEATURE REVIEWS
Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers TD Gould, JA Quiroz, J Singh, CA Zarate Jr, HK Manji
The authors discussed approaches to develop novel treatments specifically for bipolar disorder. They described targets of current mood stabilizers and discussed possible methods to design novel drugs that mimic these mechanisms. Molecular and cellular targets of current mood stabilizers include lithium inhibitable enzymes (inositol monophosphatase, glycogen synthase kinase-3 (GSK-3)), in addition to targets of valproate and carbamazepine. The authors anticipate that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments for those who suffer from this devastating illness.
Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology JA Quiroz, J Singh, TD Gould, KD Denicoff, CA Zarate Jr, HK Manji Bipolar disorder is a common, severe, chronic, and often life-threatening illness, associated with significant comorbidity and for which new therapeutic agents are needed. The authors proposed that strategies focused on the underlying pathophysiology of the illness at levels of intracellular signaling cascades, as well as impairments of cellular plasticity and resilience in critical neuronal circuits, will lead the development of improved medications. These strategies included targeting neurotrophic pathways, glucocorticoid signaling, phosphodiesterase activity and glutamatergic throughput.
ORIGINAL RESEARCH ARTICLES
No evidence for linkage or association of neuregulin-1 (NRG1) with disease in the Irish study of highdensity schizophrenia families (ISHDSF) DL Thiselton, BT Webb, BM Neale, RC Ribble, FA O'Neill, D Walsh, BP Riley, KS Kendler
The authors investigated NRG1 gene variants for linkage and/or association to schizophrenia in the Irish study of high-density schizophrenia families (ISHDSF). They found no evidence for linkage independent of the pre-existing findings on 8p. Analysis of linkage disequilibrium (LD) across the 7-marker high-risk Icelandic/Scottish NRG1 haplotype revealed two separate regions of modest LD in the ISHDSF, neither of which showed association with schizophrenia. There is evidence that one or more schizophrenia genes exists on chromosome 22. The authors screened 10 DNA markers across this region in 779 schizophrenia families, and also tested for gender and age at illness onset. No significant evidence for linkage to schizophrenia or for linkage associated with earlier age at onset or gender was found. Mowry et al. interpreted these findings to mean that the effects of chromosome 22 schizophrenia genes were too weak to detect with this type of analysis. Mutations in the melanocortin-4 receptor gene can be detected in 1-3% of obese individuals. It was recently suggested that these mutations are also highly associated with binge eating disorder. In the current study the authors assessed the eating behavior of 43 mutation carriers. In contrast to the previous study, they found no evidence for an elevated risk for development of binge eating disorder.
Haplotype analysis of SNAP-25 suggests a role in the etiology of ADHD J Mill, S Richards, J Knight, S Curran, E Taylor, P Asherson Several lines of evidence suggest a role for SNAP-25 in the etiology of ADHD. Most notable is the coloboma mouse mutant, which displays spontaneous hyperactivity and is hemizygous for a deletion spanning this gene. In this study, the SNAP-25 gene was screened using DHPLC. Several polymorphisms were detected and tested for association in a clinical ADHD sample. Some evidence was found to suggest association of SNAP-25 with ADHD, although the precise causal functional variant is yet to be ascertained and further evidence is needed to confirm this finding.
